CD19 CAR T / Nationwide Children's - LARVOL DELTA

Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis. (PubMed, Transplant Cell Ther) - "Infections are common and can result in inferior outcomes after ide-cel, underscoring the importance of risk stratification, surveillance, and stringent infection prevention strategies to optimize outcomes."

Journal • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Transplantation

HARNESSING GRAFT-VERSUS-LEUKEMIA ALLOREACTIVITY TO TREAT MULTI-REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HSCT (EBMT 2026) - "Particular attention was given to the rationale, timing, and outcomes of combining inotuzumab ozogamicin with haplo-DLI and IFN-α...Marrow relapse after CD19 CAR-T and another relapse after CD22 CAR-T prompted a second HSCT—a maternal haploidentical transplant—on 4/21/2020...The patient subsequently developed severe chronic SR-GvHD requiring prolonged therapy with MSCs, ruxolitinib, belumosudil, and axatilimab... This case demonstrates that intentionally harnessed GvL—via haploidentical DLI augmented with IFN-α—can produce deep, durable remission in profoundly multi-refractory pediatric ALL. Although associated with significant acute and chronic GvHD, coordinated multidisciplinary management enabled control of both leukemia and immune dysregulation. These findings support further evaluation of cytokine-enhanced DLI strategies as a salvage modality for high-risk pediatric patients who relapse despite HSCT and advanced cellular therapies."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • CD22 • IFNA1

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review. (PubMed, Blood Adv) - "Outcomes for patients with HD and concurrent EMD or CNS disease were worse than for iBM patients with HD. In summary, CD19-CAR may be an effective option for relapsed/refractory B-ALL with active EMD or CNS disease, but concurrent HD predicts inferior outcomes, prompting consideration of enhanced pre-infusion evaluation and treatment."

Journal • Retrospective data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Nationwide Children's Hospital | Trial completion date: Dec 2027 ➔ Dec 2035 | Trial primary completion date: Dec 2026 ➔ Dec 2030

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD19

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. (PubMed, Blood Adv) - "The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 R/R LBCL patients receiving commercial CD19 CAR T-cell (n=2804 axicabtagene ciloleucel, n=546 tisagenlecleucel) from December 2017 to June 2022. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell. Furthermore, results identify patients at heightened risk for infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy."

Journal • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Design of the First Clinical Trial of AAV Gene Therapy in Immuno-Oncology (SENTRY-ALL): A Single Dose CD3/CD19 Bi-Specific T-Cell Engager for the Treatment of CD19+ B-Cell Acute Lymphoblastic Leukemia (ASGCT 2025) - P1/2 | "VNX-101 is an investigational adeno-associated virus (AAV) gene therapy developed to express a secreted anti-CD19/anti-CD3 scFv diabody (termed GP101)...Prior blinatumomab and/or CD19 CAR T-cell treatment is allowed...This trial aims to provide the first clinical experience in the use of AAV gene therapy as a new paradigm for cancer immunotherapy. Disease Focus of Abstract:Cancer Hematologic"

Clinical • Gene therapy • Immuno-oncology • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Gene Therapies • Hematological Malignancies • Leukemia • Lymphoma • Oncology